Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new ...

Danaher (NYSE:DHR) closed 2025 with what management described as a “strong finish” and better-than-expected performance ...

The COVID-19 pandemic led to a disruption of infection rates of many common respiratory diseases in children. However, the ...

Q4 2025 Earnings Call January 28, 2026 8:00 AM ESTCompany ParticipantsJohn Bedford - Vice President of Investor ...

Roche’s cobas® BV/CV PCR assay aims to address frequent misdiagnosis of bacterial vaginosis and Candida vaginitis. The duplex test detects both conditions from one swab with high specificity, enabling ...

Danaher Corporation (NYSE:DHR) Q4 2025 Earnings Call Transcript January 28, 2026 Danaher Corporation beats earnings ...

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period ...

A biotech pioneer introduces innovative diagnostic kits designed to slash costs, speed up results, and support timely ...

The "Proteinase K - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The Proteinase K market is projected to ...

COVID-19’s danger lay in its invisibility. The SARS-CoV-2 virus is highly contagious and can be passed on by people with light or no symptoms, making it extremely difficult to track and contain. But ...

Co-Diagnostics lost its place on the Nasdaq after consistently failing to meet the exchange's minimum bid price requirement. In a last-ditch effort to regain compliance, the company executed a ...

Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2025 results on Jan. 29, before market open. In the last reported quarter, earnings of $5.79 per share beat the Zacks Consensus ...